Abstract:

What are adverse drug reactions and their causes. How the drug-drug interactions impart toxicity and how we can address them. What are CPYs? Where are they present? What are their functions and how to check activity against them. What is hERG and how it is relevant to drug discovery. Do we really need to address hERG? What impact it has in drug discovery hERG is inhibited. When to check for hERG and CYP's and how it will help in lead optimization. Once we understand their importance and the role we can modulate the properties in a drug molecules to reduce the effect of drug-drug interactions and prevent toxicity and improve cardiac safety.